Butterfly Network, Inc.
BFLY Healthcare Medical Devices
Butterfly Network, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $97.6 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 16.7% and free cash flow fell 113.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BFLY
Butterfly Network, Inc. (BFLY) EV/Sales
As of 16 October 2026, Butterfly Network, Inc. (BFLY) trades at a EV/Sales of 16.3×. Over the past ten years it has ranged from 0.0× (December 2020) to 42.5× (June 2021); the current reading is higher than 85% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.6× | 13.21% |
| FY2024 | 7.6× | 266.28% |
| FY2023 | 2.1× | (46.16%) |
| FY2022 | 3.9× | (69.59%) |
| FY2022 | 12.7× | 0.20% |
| FY2021 | 12.7× | 435.08% |
| FY2021 | 2.4× | (3.42%) |
| FY2020 | 2.5× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.0× | 105.86% |
| Mar 2026 | 9.3× | 7.21% |
| Dec 2025 | 8.6× | 92.69% |
| Sep 2025 | 4.5× | (2.61%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| NVCR NovoCure Limited compare | 2.0× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)